Accenture Announces Collaboration with Bayer to Streamline Drug Development Processes through INTIENT Clinical Platform

NEW YORK; Sept. 16, 2019 – Accenture (NYSE: ACN) has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing platform, creating actionable insights to accelerate drug development and improve patient outcomes.
September 16, 2019

Better Collaboration Between Pharma and Patient Organizations Would Improve Patient Care, Accenture Study Finds

FRANKFURT and NEW YORK; Aug. 6, 2019 ‒ To deliver better patient experiences, pharmaceutical companies should collaborate with nonprofit organizations that provide support services and advocate for patients, according to a new study from Accenture (NYSE: ACN).
 
August 07, 2019

Accenture Introduces INTIENT™, an Innovative Platform to Advance the Discovery, Development and Delivery of Patient Treatments

NEW YORK; May 16, 2019 – Accenture (NYSE: ACN) today introduced INTIENT™, a technology platform that vastly improves the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients. 
May 16, 2019

Accenture Completes Acquisition of ESP

NEW YORK and DUBLIN, Ireland; May 1, 2019 – Accenture (NYSE: ACN) has completed the acquisition of Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry that is headquartered in Cork, Ireland.
May 01, 2019

“New Science” is Leading Growth While Changing the Market Dynamics of the Biopharma Industry, According to New Research from Accenture

NEW YORK; April 4, 2019 – The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).
April 04, 2019

Accenture to Acquire ESP to Help Life Sciences Clients Digitize and Transform Manufacturing Operations

NEW YORK and DUBLIN, Ireland; Mar. 5, 2019 – Accenture (NYSE: ACN) has agreed to acquire Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry that is headquartered in Cork, Ireland, serving clients around the globe. Upon close, ESP will join Accenture Industry X.0, which helps clients master the digital reinvention of industry, strengthening Accenture’s capabilities to transform manufacturing for pharmaceutical, biotech and medical device clients globally.
March 05, 2019

Ayasdi Named Accenture HealthTech Innovation Challenge Innovation Champion

SAN FRANCISCO; Jan. 8, 2019 – Ayasdi has been named the Accenture HealthTech Innovation Challenge Innovation Champion, competing with more than 1,100 companies for the title. The competition pairs leading-edge startups with prominent health and life sciences organizations to develop innovative technology solutions that improve the way people access and manage healthcare.
January 08, 2019

Four Finalists in US and Canada Selected for Accenture HealthTech Innovation Challenge

NEW YORK; Dec. 21, 2018 – Using conversational artificial intelligence to improve care management and leveraging patient experiences to incentivize patients in their own health journey are among the innovative solutions being developed by the four North America-based finalists selected for the Accenture HealthTech Innovation Challenge.
December 21, 2018

Pierre Fabre Turns to Accenture to Digitize Corporate and Manufacturing Functions with SAP® S/4HANA®

PARIS; Dec. 11, 2018 – Pierre Fabre has selected Accenture (NYSE: ACN) to build an intelligent information technology (IT) platform to support and improve the performance of a range of functions including finance, accounting, procurement, order management and manufacturing  essential to the company’s global operations. The program is part of one of the most significant and strategic transformation initiatives ever undertaken at the French multinational health and beauty care company.
December 11, 2018

Accenture Expands Platform for Drug Discovery and Innovation with Creation of Life Sciences Partner Ecosystem

NEW YORK and LAS VEGAS; Nov. 26, 2018 – Accenture (NYSE: ACN) has created an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes.
November 26, 2018